Farmas USA

CEMP

CEMPRA (NASDAQ: CEMP): Q4 EPS of -$0.60 misses by $0.01.

Revenue of $7.95M (+37.3% Y/Y) beats by $0.87M.

Solithromycin # FAIL to demonstrate non-inferiority to standard of care treatment in initial cohort of 262 pts in Ph3 gonorrhea study.

CEMPsuspends NASH development program for Solithromycin.

it has closed the exploratory study evaluating long-term systemic solithromycin to treat airway inflammation in patients with chronic obstructive pulmonary disease (COPD) based on safety data from several of the initial subjects.

, we recently initiated companywide cost and personnel reductions. These actions have resulted in an approximately 67 percent reduction in our workforce, from 136 to 45 employees, and significant reductions in external spending related to commercial preparedness and non-essential activities. The principal objective of the reductions is to enable us to conserve our financial resources as we evaluate the best path forward with our existing pipeline and potential business development opportunities."

http://seekingalpha.com/news/3247016-cempra-misses-0_01-beats-revenue

KITE

Met Primary Endpoint of Objective Response Rate p<0.0001

Bastardo: Seems like 6-month CR rate in DLBCL held up well compared to what we saw at 3 months. 31% from 33%. Agree? No?

http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20170228:nBw9sNpXZa

ELEVATE YOUR PARTNERING STRATEGY WITH LEADERS IN THE GLOBAL BIOTECH COMMUNITY

March 20–22, 2017
CCIB Convention Centre
Barcelona, Spain

https://ebdgroup.knect365.com/bioeurope-spring/?utm_source=MSPO&utm_medium=web&utm_term=Labiotech&utm_campaign=BES17

2300 pavos de entrada. La única opción es colarse como prensa. Para los que tengáis blog: https://app.smartsheet.com/b/form?EQBCT=bb190b9df39c4960af92efd88b77349d

Igual es el momento de montar uno. Mientras tanto, me ofrezco de florero.

KITE

Kite’s CAR-T cancer therapy shows strong results as company races to win FDA approval

A hopeful sign: the number in complete remission at six months — 36 percent — is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well.

Six months after treatment, 41 percent still had a partial response (cancer shrunk at least in half) and 36 percent were in complete remission (no sign of disease).

There were no cases of swelling and fluid in the brain in this or any other study testing Kite’s treatment, company officials said. That contrasts with Juno Therapeutics, which has had a CAR-T study put on hold twice after five patient deaths due to this problem.

Results were released by the company and have not been published or reviewed by other experts. Full results will be presented at the American Association for Cancer Research conference in April.

The company plans to seek approval from the Food and Drug Administration by the end of March and in Europe later this year.

https://www.statnews.com/2017/02/28/cancer-car-t-kite/

pues muchos años relacionados con temas financieros y contables...o tener alguién que te lo chive ;-)

TEVA

Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia. Pdufa August 30, 2017

¡Y yo que te hacía joven! ¿Secretaria no necesitas? :D